![Matthew Fry](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Net worth: 2 M $ as of 31/05/2026
Mr. Matthew Fry is a Chief Executive Officer & Managing Director at Am Diagnostics Pty Ltd. He is on the Board of Directors at Paradigm Biopharmaceuticals Ltd.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BLINKLAB LIMITED 1.85% | 21/08/2025 | 2,833,333 ( 1.85% ) | 1 M $ | 31/05/2026 |
| 02/06/2026 | 1,596,300 ( 0.3% ) | 189 513 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| PARADIGM BIOPHARMACEUTICALS LIMITED | Director/Board Member | 04/03/2024 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 1 |
|---|---|
Paradigm Biopharmaceuticals Ltd.
 Paradigm Biopharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Engages in repurposing the drug, pentosan polysulphate sodium for the treatment of bone marrow edema | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
